The effect of palbociclib on cell cycle progression was maintained for at least 2 weeks (Fig. 3A), contrary to the rapidly developing resistance to CDK4/6 inhibition described in breast cancer cells [80]. This evidence concerns the gene CDK4 and breast carcinoma.